{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T02:35:23Z","timestamp":1770518123658,"version":"3.49.0"},"reference-count":25,"publisher":"Becaris Publishing Limited","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"published-print":{"date-parts":[[2019,4]]},"abstract":"\n Aim:<\/jats:bold>\n Head-to-head clinical trials of teriflunomide (TFM) versus dimethyl fumarate (DMF) have not been conducted.\n Objectives:<\/jats:bold>\n To compare the real-world effectiveness of TFM versus DMF.\n Methods:<\/jats:bold>\n Anonymized data were collected from patients with relapsing multiple sclerosis (MS) initiating treatment with teriflunomide (N\u00a0=\u00a050) or DMF (N\u00a0=\u00a050).\n Results:<\/jats:bold>\n On follow-up magnetic resonance imaging (MRI)\u00a0compared with baseline, with TFM versus DMF treatment, the proportion of patients with new\/enlarging T2 or gadolinium-enhancing lesions was 30.0 versus 40.0% (p =\u00a00.2752). However, median annualized percent whole brain volume change was -0.1 versus -0.5 (p =\u00a00.0212). There were no significant treatment differences on additional MRI and clinical end points and no unexpected safety signals.\n Conclusion:<\/jats:bold>\n The effectiveness of teriflunomide was superior to DMF on whole brain atrophy and similar to DMF on other MRI\/clinical end points.\n <\/jats:p>","DOI":"10.2217\/cer-2018-0135","type":"journal-article","created":{"date-parts":[[2019,2,13]],"date-time":"2019-02-13T09:58:23Z","timestamp":1550051903000},"page":"305-316","source":"Crossref","is-referenced-by-count":17,"title":["Comparative effectiveness of teriflunomide and dimethyl fumarate in patients with relapsing forms of MS in the retrospective real-world Teri-RADAR study"],"prefix":"10.57264","volume":"8","author":[{"given":"Robert","family":"Zivadinov","sequence":"first","affiliation":[{"name":"Buffalo Neuroimaging Analysis Center, University at Buffalo, Buffalo, NY, USA"},{"name":"Center for Biomedical Imaging at Clinical Translational Science Institute, University at Buffalo, Buffalo, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiren","family":"Kresa-Reahl","sequence":"additional","affiliation":[{"name":"Providence Multiple Sclerosis Center, Providence St Joseph Health, Portland, OR, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bianca","family":"Weinstock-Guttman","sequence":"additional","affiliation":[{"name":"Jacobs Comprehensive MS Center for Treatment & Research, Jacobs School of Medicine & Biomedical Sciences, University at Buffalo, Buffalo, NY,\u00a0USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keith","family":"Edwards","sequence":"additional","affiliation":[{"name":"Multiple Sclerosis Center of Northeastern New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chakkarin","family":"Burudpakdee","sequence":"additional","affiliation":[{"name":"IQVIA, Fairfax, VA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niels","family":"Bergsland","sequence":"additional","affiliation":[{"name":"Buffalo Neuroimaging Analysis Center, University at Buffalo, Buffalo, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael G","family":"Dwyer","sequence":"additional","affiliation":[{"name":"Buffalo Neuroimaging Analysis Center, University at Buffalo, Buffalo, NY, USA"},{"name":"Center for Biomedical Imaging at Clinical Translational Science Institute, University at Buffalo, Buffalo, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bhupendra","family":"Khatri","sequence":"additional","affiliation":[{"name":"Wheaton Franciscan Healthcare, Center for Neurological Disorders, Milwaukee, WI, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karthinathan","family":"Thangavelu","sequence":"additional","affiliation":[{"name":"Sanofi, Cambridge, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey","family":"Chavin","sequence":"additional","affiliation":[{"name":"Sanofi, Cambridge, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matt","family":"Mandel","sequence":"additional","affiliation":[{"name":"Sanofi, Cambridge, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stanley","family":"Cohan","sequence":"additional","affiliation":[{"name":"Providence Multiple Sclerosis Center, Providence St Joseph Health, Portland, OR, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"36897","reference":[{"key":"e_1_3_6_3_2","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.1600-0404.2010.01444.x","article-title":"Pathophysiology of multiple sclerosis and the place of teriflunomide","volume":"124","author":"Gold R","year":"2011","unstructured":"Gold R , Wolinsky JS . Pathophysiology of multiple sclerosis and the place of teriflunomide . Acta Neurol. Scand. 124 , 75 \u2013 84 ( 2011 ).","journal-title":"Acta Neurol. Scand."},{"key":"e_1_3_6_4_2","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S1474-4422(13)70308-9","article-title":"Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, Phase 3 trial","volume":"13","author":"Confavreux C","year":"2014","unstructured":"Confavreux C , O'Connor P , Comi G Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, Phase 3 trial . Lancet Neurol. 13 , 247 \u2013 256 ( 2014 ).","journal-title":"Lancet Neurol."},{"key":"e_1_3_6_5_2","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1056\/NEJMoa1014656","article-title":"Randomized trial of oral teriflunomide for relapsing multiple sclerosis","volume":"365","author":"O'Connor P","year":"2011","unstructured":"O'Connor P , Wolinsky JS , Confavreux C Randomized trial of oral teriflunomide for relapsing multiple sclerosis . N. Engl. J. Med. 365 , 1293 \u2013 1303 ( 2011 ).","journal-title":"N. Engl. J. Med."},{"key":"e_1_3_6_6_2","doi-asserted-by":"crossref","first-page":"e390","DOI":"10.1212\/NXI.0000000000000390","article-title":"Teriflunomide slows BVL in relapsing MS: A reanalysis of the TEMSO MRI data set using SIENA","volume":"4","author":"Radue EW","year":"2017","unstructured":"Radue EW , Sprenger T , Gaetano L Teriflunomide slows BVL in relapsing MS: A reanalysis of the TEMSO MRI data set using SIENA . Neurol. Neuroimmunol. Neuroinflamm. 4 , e390 ( 2017 ).","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"e_1_3_6_7_2","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1007\/s11910-013-0394-8","article-title":"Dimethyl fumarate for treatment of multiple sclerosis: mechanism of action, effectiveness, and side effects","volume":"13","author":"Linker RA","year":"2013","unstructured":"Linker RA , Gold R . Dimethyl fumarate for treatment of multiple sclerosis: mechanism of action, effectiveness, and side effects . Curr. Neurol. Neurosci. Rep 13 , 394 ( 2013 ).","journal-title":"Curr. Neurol. Neurosci. Rep"},{"key":"e_1_3_6_8_2","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1056\/NEJMoa1206328","article-title":"Placebo-controlled Phase 3 study of oral BG-12 or glatiramer in multiple sclerosis","volume":"367","author":"Fox RJ","year":"2012","unstructured":"Fox RJ , Miller DH , Phillips JT Placebo-controlled Phase 3 study of oral BG-12 or glatiramer in multiple sclerosis . N. Engl. J. Med. 367 , 1087 \u2013 1097 ( 2012 ).","journal-title":"N. Engl. J. Med."},{"key":"e_1_3_6_9_2","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa1114287","article-title":"Placebo-controlled Phase 3 study of oral BG-12 for relapsing multiple sclerosis","volume":"367","author":"Gold R","year":"2012","unstructured":"Gold R , Kappos L , Arnold DL Placebo-controlled Phase 3 study of oral BG-12 for relapsing multiple sclerosis . N. Engl. J. Med. 367 , 1098 \u2013 1107 ( 2012 ).","journal-title":"N. Engl. J. Med."},{"key":"e_1_3_6_10_2","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1111\/jon.12411","article-title":"An observational study to assess brain MRI change and disease progression in multiple sclerosis clinical practice \u2013 the MS-MRIUS study","volume":"27","author":"Zivadinov R","year":"2017","unstructured":"Zivadinov R , Khan N , Medin J An observational study to assess brain MRI change and disease progression in multiple sclerosis clinical practice \u2013 the MS-MRIUS study . J. Neuroimaging 27 , 339 \u2013 347 ( 2017 ).","journal-title":"J. Neuroimaging"},{"key":"e_1_3_6_11_2","doi-asserted-by":"crossref","first-page":"289","DOI":"10.3174\/ajnr.A5442","article-title":"Feasibility of brain atrophy measurement in clinical routine without prior standardization of the MRI protocol: results from MS-MRIUS, a longitudinal observational, multicenter real-world outcome study in patients with relapsing-remitting MS","volume":"39","author":"Zivadinov R","year":"2018","unstructured":"Zivadinov R , Bergsland N , Korn JR Feasibility of brain atrophy measurement in clinical routine without prior standardization of the MRI protocol: results from MS-MRIUS, a longitudinal observational, multicenter real-world outcome study in patients with relapsing-remitting MS . AJNR Am. J. Neuroradiol. 39 , 289 \u2013 295 ( 2018 ).","journal-title":"AJNR Am. J. Neuroradiol."},{"key":"e_1_3_6_12_2","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s40263-017-0482-4","article-title":"Assessing \u2018no evidence of disease activity\u2019 status in patients with relapsing-remitting multiple sclerosis receiving fingolimod in routine clinical practice: a retrospective analysis of the Multiple Sclerosis Clinical and Magnetic Resonance Imaging Outcomes in the USA (MS-MRIUS) study","volume":"32","author":"Weinstock-Guttman B","year":"2018","unstructured":"Weinstock-Guttman B , Medin J , Khan N Assessing \u2018no evidence of disease activity\u2019 status in patients with relapsing-remitting multiple sclerosis receiving fingolimod in routine clinical practice: a retrospective analysis of the Multiple Sclerosis Clinical and Magnetic Resonance Imaging Outcomes in the USA (MS-MRIUS) study . CNS Drugs 32 , 75 \u2013 84 ( 2018 ).","journal-title":"CNS Drugs"},{"key":"e_1_3_6_13_2","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1148\/radiol.13122424","article-title":"Thalamic atrophy is associated with development of clinically definite multiple sclerosis","volume":"268","author":"Zivadinov R","year":"2013","unstructured":"Zivadinov R , Havrdova E , Bergsland N Thalamic atrophy is associated with development of clinically definite multiple sclerosis . Radiology 268 , 831 \u2013 841 ( 2013 ).","journal-title":"Radiology"},{"key":"e_1_3_6_14_2","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1007\/s00415-014-7616-0","article-title":"Effect of glatiramer acetate three-times weekly on the evolution of new, active multiple sclerosis lesions into T1-hypointense \u201cblack holes\u201d: a post hoc magnetic resonance imaging analysis","volume":"262","author":"Zivadinov R","year":"2015","unstructured":"Zivadinov R , Dwyer M , Barkay H , Steinerman JR , Knappertz V , Khan O . Effect of glatiramer acetate three-times weekly on the evolution of new, active multiple sclerosis lesions into T1-hypointense \u201cblack holes\u201d: a post hoc magnetic resonance imaging analysis . J. Neurol. 262 , 648 \u2013 653 ( 2015 ).","journal-title":"J. Neurol."},{"key":"e_1_3_6_15_2","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1006\/nimg.2002.1040","article-title":"Accurate, robust, and automated longitudinal and cross-sectional brain change analysis","volume":"17","author":"Smith SM","year":"2002","unstructured":"Smith SM , Zhang Y , Jenkinson M Accurate, robust, and automated longitudinal and cross-sectional brain change analysis . Neuroimage 17 , 479 \u2013 489 ( 2002 ).","journal-title":"Neuroimage"},{"key":"e_1_3_6_16_2","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.nicl.2017.06.022","article-title":"Neurological software tool for reliable atrophy measurement (NeuroSTREAM) of the lateral ventricles on clinical- quality T2-FLAIR MRI scans in multiple sclerosis","volume":"15","author":"Dwyer MG","year":"2017","unstructured":"Dwyer MG , Silva D , Bergsland N Neurological software tool for reliable atrophy measurement (NeuroSTREAM) of the lateral ventricles on clinical- quality T2-FLAIR MRI scans in multiple sclerosis . Neuroimage Clin. 15 , 769 \u2013 779 ( 2017 ).","journal-title":"Neuroimage Clin."},{"key":"e_1_3_6_17_2","first-page":"93","article-title":"Establishing pathological cut-offs of brain atrophy rates in multiple sclerosis","volume":"87","author":"De Stefanox N","year":"2016","unstructured":"De Stefanox N , Stromillo ML , Giorgio A Establishing pathological cut-offs of brain atrophy rates in multiple sclerosis . J. Neurol. Neurosurg. Psychiatry 87 , 93 \u2013 99 ( 2016 ).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"e_1_3_6_18_2","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.nicl.2018.02.009","article-title":"Establishing pathological cut-offs for lateral ventricular volume expansion rates","volume":"18","author":"Dwyer MG","year":"2018","unstructured":"Dwyer MG , Hagemeier J , Bergsland N Establishing pathological cut-offs for lateral ventricular volume expansion rates . Neuroimage Clin. 18 , 494 \u2013 501 ( 2018 ).","journal-title":"Neuroimage Clin."},{"key":"e_1_3_6_19_2","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.msard.2016.10.010","article-title":"Comparing outcomes from clinical studies of oral disease-modifying therapies (dimethyl fumarate, fingolimod, and teriflunomide) in relapsing MS: Assessing absolute differences using a number needed to treat analysis","volume":"10","author":"Freedman MS","year":"2016","unstructured":"Freedman MS , Montalban X , Miller AE Comparing outcomes from clinical studies of oral disease-modifying therapies (dimethyl fumarate, fingolimod, and teriflunomide) in relapsing MS: Assessing absolute differences using a number needed to treat analysis . Mult. Scler. Relat. Disord. 10 , 204 \u2013 212 ( 2016 ).","journal-title":"Mult. Scler. Relat. Disord."},{"key":"e_1_3_6_20_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000127972","article-title":"Efficacy of disease-modifying therapies in relapsing remitting multiple sclerosis: a systematic comparison","volume":"60","author":"Freedman MS","year":"2008","unstructured":"Freedman MS , Hughes B , Mikol DD Efficacy of disease-modifying therapies in relapsing remitting multiple sclerosis: a systematic comparison . Eur. Neurol. 60 , 1 \u2013 11 ( 2008 ).","journal-title":"Eur. Neurol."},{"key":"e_1_3_6_21_2","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/S1474-4422(14)70191-7","article-title":"Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, Phase 3 trial","volume":"13","author":"Miller AE","year":"2014","unstructured":"Miller AE , Wolinsky JS , Kappos L Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, Phase 3 trial . Lancet Neurol. 13 , 977 \u2013 986 ( 2014 ).","journal-title":"Lancet Neurol."},{"key":"e_1_3_6_22_2","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1136\/jnnp-2012-304094","article-title":"Brain atrophy and lesion load predict long term disability in multiple sclerosis","volume":"84","author":"Popescu V","year":"2013","unstructured":"Popescu V , Agosta F , Hulst HE Brain atrophy and lesion load predict long term disability in multiple sclerosis . J. Neurol. Neurosurg. Psychiatry 84 , 1082 \u2013 1091 ( 2013 ).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"e_1_3_6_23_2","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1080\/03007995.2018.1458708","article-title":"No evidence of disease activity in patients receiving fingolimod at private or academic centers in clinical practice: a retrospective analysis of the Multiple Sclerosis, Clinical, and Magnetic Resonance Imaging Outcomes in the USA (MS-MRIUS) study","volume":"34","author":"Zivadinov R","year":"2018","unstructured":"Zivadinov R , Khan N , Korn JR No evidence of disease activity in patients receiving fingolimod at private or academic centers in clinical practice: a retrospective analysis of the Multiple Sclerosis, Clinical, and Magnetic Resonance Imaging Outcomes in the USA (MS-MRIUS) study . Curr. Med. Res. Opin. 34 , 1431 \u2013 1440 ( 2018 ).","journal-title":"Curr. Med. Res. Opin."},{"key":"e_1_3_6_24_2","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/jon.12518","article-title":"Fingolimod's impact on MRI brain volume measures in multiple sclerosis: results from MS-MRIUS","volume":"28","author":"Zivadinov R","year":"2018","unstructured":"Zivadinov R , Medin J , Khan N Fingolimod's impact on MRI brain volume measures in multiple sclerosis: results from MS-MRIUS . J. Neuroimaging 28 , 399 \u2013 405 ( 2018 ).","journal-title":"J. Neuroimaging"},{"key":"e_1_3_6_25_2","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.msard.2018.09.037","article-title":"Impact of fingolimod on clinical and magnetic resonance imaging outcomes in routine clinical practice: a retrospective analysis of the Multiple Sclerosis, Clinical and MRI Outcomes in the USA (MS-MRIUS) study","volume":"27","author":"Zivadinov R","year":"2018","unstructured":"Zivadinov R , Medin J , Khan N Impact of fingolimod on clinical and magnetic resonance imaging outcomes in routine clinical practice: a retrospective analysis of the Multiple Sclerosis, Clinical and MRI Outcomes in the USA (MS-MRIUS) study . Mult. Scler. Relat. Disord. 27 , 65 \u2013 73 ( 2018 ).","journal-title":"Mult. Scler. Relat. Disord."},{"key":"e_1_3_6_26_2","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s40263-017-0482-4","article-title":"Assessing \u2018no evidence of disease activity\u2019 status in patients with relapsing-remitting multiple sclerosis receiving fingolimod in routine clinical practice: a retrospective analysis of the Multiple Sclerosis Clinical and Magnetic Resonance Imaging in the USA (MS-MRIUS) Study","volume":"32","author":"Weinstock-Guttman B","year":"2018","unstructured":"Weinstock-Guttman B , Medin J , Khan N Assessing \u2018no evidence of disease activity\u2019 status in patients with relapsing-remitting multiple sclerosis receiving fingolimod in routine clinical practice: a retrospective analysis of the Multiple Sclerosis Clinical and Magnetic Resonance Imaging in the USA (MS-MRIUS) Study . CNS Drugs 32 , 75 \u2013 84 ( 2018 ).","journal-title":"CNS Drugs"},{"key":"e_1_3_6_27_2","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1212\/01.wnl.0000316810.01120.05","article-title":"Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis","volume":"71","author":"Zivadinov R","year":"2008","unstructured":"Zivadinov R , Reder AT , Filippi M Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis . Neurology 71 , 136 \u2013 144 ( 2008 ).","journal-title":"Neurology"}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/becarispublishing.com\/doi\/pdf\/10.2217\/cer-2018-0135","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,19]],"date-time":"2023-03-19T13:13:44Z","timestamp":1679231624000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.2217\/cer-2018-0135"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["10.2217\/cer-2018-0135"],"URL":"https:\/\/doi.org\/10.2217\/cer-2018-0135","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"value":"2042-6305","type":"print"},{"value":"2042-6313","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4]]}}}